0001104659-24-048303.txt : 20240417
0001104659-24-048303.hdr.sgml : 20240417
20240417160519
ACCESSION NUMBER: 0001104659-24-048303
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240416
FILED AS OF DATE: 20240417
DATE AS OF CHANGE: 20240417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fortress Biotech, Inc.
CENTRAL INDEX KEY: 0001429260
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38114
FILM NUMBER: 24850993
BUSINESS ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
BUSINESS PHONE: 781-652-4500
MAIL ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
FORMER NAME:
FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC
DATE OF NAME CHANGE: 20080310
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVENUE THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001644963
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 474113275
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
BUSINESS PHONE: 781-652-4500
MAIL ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
4
1
tm2412005-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-04-16
1
0001644963
AVENUE THERAPEUTICS, INC.
ATXI
0001429260
Fortress Biotech, Inc.
1111 KANE CONCOURSE SUITE 301
BAY HARBOR ISLANDS
FL
33154
0
0
1
0
0
COMMON STOCK, PAR VALUE $0.0001
2024-04-16
4
A
0
413507
0.00
A
3547393
D
The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 413,507 shares were granted by the Issuer to the Reporting Person following the closing of an equity financing.
/s/ Samuel Berry, General Counsel and Authorized Agent
2024-04-17